Abbott

Next Generation ICD
and CRT-D Solutions

HIGH-VOLTAGE HUGE IMPACT



POWERFULLY CONNECTED

SMARTPHONE CONNECTIVITY

Health technology is reshaping the way you and your patients connect. It's changing what's possible with patient follow-up care. Abbott's ICD and CRT-D solutions offer built-in smartphone connectivity — ensuring continuous patient engagement so that you may have earlier detection of clinically relevant events.

GREATER ENGAGEMENT

The secure myMerlinPulse™ app streamlines remote monitoring with your patients and encourages greater patient engagement. Potential benefits include:

FOR YOU

- Improved patient compliance
- Reduction in clinic burden
- Simplified workflow

FOR YOUR PATIENTS

- Opportunity for better quality of life
- Peace of mind with automatic daily checks
- Discretion and freedom to go anywhere, anytime

97%

of patients using Abbott's app-based remote monitoring were compliant.[1]



SECURED DATA AND INFORMATION

You don't have to worry about the safety of patient information with Abbott. The myMerlinPulse app transmits device status and information to the Merlin.net™ Patient Care Network through a secure, encrypted connection. Access to patient information is restricted to authorized clinic users.

PIONEERING DYNAMIC TECHNOLOGY

PATIENT-FOCUSED ENHANCEMENTS

The well-being of patients is at the forefront of every Abbott innovation. Our ICD and CRT-D solutions help you deliver accurate, optimized care with features you can intuitively program to meet your patients' changing needs.

ADVANCED CRT OPTIMIZATION

and ease of programming with SyncAV™ *Plus* CRT technology and MultiPoint™ pacing.[2,3]

ENHANCED DETECTION AND TREATMENT

of challenging ventricular arrhythmias with Abbott's unique discriminator – VF Therapy Assurance.[4]

REDUCE INAPPROPRIATE THERAPY

with ShockGuard™ technology's optimized ICD arrhythmia detection.[5]

SAFER MANAGEMENT OF CARE

with DeFT Response™ technology – the industry's most flexible option for the management of DFT.[6]

POWERFUL, LONG-LASTING THERAPY

with a small, contoured shape designed to enhance quality of life with comfort and fewer anticipated complications.

1.5 AND 3T MRI READY SOLUTIONS*

offer patients better and more efficient access to the care they need, improving outcomes and peace of mind.

SMARTPHONE-ENABLED REMOTE MONITORING

encourages reliable patient engagement, offering patients greater discretion and freedom versus traditional bedside monitors.

* For additional information about specific MR Conditional ICDs, CRT-Ds and leads, including scan parameters, warnings, precautions, adverse conditions to MRI scanning, and potential adverse events, please refer to the Abbott MRI Ready Systems Manual at medical.abbott/manuals.

LIFE-CHANGING THERAPY

Every patient deserves access to life-changing therapy. Abbott's ICD and CRT-D solutions are designed to seamlessly integrate into your patients' day-to-day lives, making it possible for you to achieve clinically meaningful outcomes.

POWERFUL THERAPY ASSURANCE

98.4%

of patients did not receive inappropriate shocks at 1 year (CI: 97.2 -99.2, $p<0.0001$).[5]

>800

patients annually with challenging arrhythmias could have their lives saved because of VF Therapy Assurance.[4]

ADVANCED CRT OPTIMIZATION

100%

of patients had a narrower QRS when traditional SyncAV™ CRT technology was optimized.[7]

> CRT induced QRS narrowing has been shown to improve clinical outcomes for heart failure patients.[8,9]

22%

fewer heart failure hospitalizations for patients with SyncAV CRT technology enabled versus patients with the technology disabled.[2]



EMPOWERING YOU.
EMPOWERING YOUR PATIENTS.
POWERED BY ABBOTT.

References

1. Piorkowski C, et al. Early real-world adoption of mobile remote monitoring using the Confirm Rx Insertable Cardiac Monitor. Poster presented at: APHRS; 2018.
2. Varma, N., Gain in CRT Efficacy with Dynamic Electrical Optimization: Real World Effect of SyncAV™ CRT on Heart Failure Hospitalizations. Poster presented at EHRA. May 2020. https://www.escardio.org/Sub-specialty-communities/European-Heart-Rhythm-Association-%28EHRA%29/Research-and-Publications/EHRA Essentials-4-You#Ibt. Accessed May 15, 2020.
3. Musaad AMA, Bokhari F, Sweidan R, et al. Long term effect of MultiPoint Pacing in Heart Failure patients on end systolic volume: preliminary results from a randomized and multicenter study in the Middle East. APHRS presentation, 2019.
4. Data on file. 60101422 Internal Validation Report. Total 2019 global high-voltage implants, all manufacturers, estimated to be 440,434 units (Source: Abbott Market Research).
5. Veltmann C, Wöhrle, Busch M, et al. Reduction of inappropriate shocks of ICDs with enhanced SVT discriminators. EUROPACE presentation; 2017.
6. Gabriels J, Budzikowski AS, Kassotis JT. Defibrillation waveform duration adjustment increases the proportion of acceptable defibrillation thresholds in patients implanted with single-coil defibrillation leads. Cardiology. 2013;124(2):71-75.
7. Varma N, O'Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7:e007489.
8. Canadian Cardiovascular Society. Clinical Significance of Electromechanical Dyssynchrony and QRS Narrowing in Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. http://doi.org/10.1016/j.cjca.2018.10.019. Accessed February 25, 2019.
9. Okafor O, Leyva F, Zegard A, et al. Changes in QRS Area and QRS Duration After Cardiac Resynchronization Therapy Predict Cardiac Mortality, Heart Failure Hospitalizations, and Ventricular Arrhythmias. J Am Heart Assoc. 2019;8:e013539. DOI:10.1161/JAHA.119.013539. https://www.ahajournals.org/doi/10.1161/JAHA.117.007489. Accessed January 14, 2020.

Abbott

One St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000
Cardiovascular.Abbott

Rx Only

Brief Summary: This product is intended for use by or under the direction of a Physician. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Intended Use: The Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices are intended to provide ventricular antitachycardia pacing and ventricular cardioversion/defibrillation. The CRT-D devices are also intended to resynchronize the right and left ventricles.

The myMerlinPulse™ mobile application is intended for use by people who have an Abbott Medical implanted heart device and access to a mobile device. The app provides remote monitoring capability of the implanted heart device by transmitting information from the patient's implanted heart device to the patient's healthcare provider.

Indications: The ICD and CRT-D devices are indicated for automated treatment of life-threatening ventricular arrhythmias. CRT-D devices are also indicated to treat symptoms in patients who have congestive heart failure with ventricular dyssynchrony.

In addition, dual chamber ICD and CRT-D devices with the AT/AF detection algorithm are indicated in patients with atrial tachyarrhythmias or those patients who are at significant risk of developing atrial tachyarrhythmias.

MR Conditional ICDs and CRT-Ds are conditionally safe for use in the MRI environment when used in a complete MR Conditional system and according to instructions in the MRI-Ready Systems manual. Scanning under different conditions may result in severe patient injury, death or device malfunction.

The myMerlinPulse™ mobile application is indicated for use by patients with supported Abbott Medical implanted heart devices.

Contraindications: Contraindications for use of the pulse generator system include ventricular tachyarrhythmias resulting from transient or correctable factors such as drug toxicity, electrolyte imbalance, or acute myocardial infarction.

The myMerlinPulse™ mobile application is contraindicated for use with any implanted medical device other than supported Abbott Medical implanted heart devices.

Adverse Events: Possible adverse events associated with the implantation of the pulse generator system include the following: Arrhythmia (for example, accelerated or induced), Bradycardia, Cardiac or venous perforation, Cardiac tamponade, Cardiogenic shock, Death, Discomfort, Embolism, Endocarditis, Erosion, Exacerbation of heart failure, Excessive fibrotic tissue growth, Extracardiac stimulation (phrenic nerve, diaphragm, pectoral muscle), Extrusion, Fluid accumulation within the device pocket, Formation of hematomas, cysts, or seromas, Heart block, Hemorrhage, Hemothorax, Hypersensitivity, including local tissue reaction or allergic reaction, Infection, Keloid formation, Myocardial damage, Nerve damage, Occlusion/Thrombus, Pericardial effusion, Pericarditis, Pneumothorax, Pulmonary edema, Syncope, Thrombosis, Valve damage. Complications reported with direct subclavian venipuncture include pneumothorax, hemothorax, laceration of the subclavian artery, arteriovenous fistula, neural damage, thoracic duct injury, cannulation of other vessels, massive hemorrhage and rarely, death. Among the psychological effects of device implantation are imagined pulsing, depression, dependency, fear of premature battery depletion, device malfunction, inappropriate pulsing, shocking while conscious, or losing pulse capability. Possible adverse device effects include complications due to the following: Abnormal battery depletion, Conductor fracture, Device-programmer communication failure, Elevated or rise in defibrillation/cardioversion threshold, Inability to defibrillate or pace, Inability to interrogate or program due to programmer or device malfunction, Incomplete lead connection with pulse generator, Inhibited therapy including defibrillation and pacing, Inappropriate therapy (for example, shocks and antitachycardia pacing [ATP] where applicable, pacing), Interruption of function due to electrical or magnetic interference, Intolerance to high rate pacing (for example dyspnea or discomfort), Lead abrasion, Lead fracture, Lead insulation damage, Lead migration or lead dislodgement, Loss of device functionality due to component failure, Pulse generator migration, Rise in DFT threshold, Rise in pacing threshold and exit block, Shunting of energy from defibrillation paddles, System failure due to ionizing radiation. Additionally, potential adverse events associated with the implantation of a coronary venous lead system include the following: Allergic reaction to contrast media, Breakage or failure of implant instruments, Prolonged exposure to fluoroscopic radiation, Renal failure from contrast media used to visualize coronary veins. Refer to the User's Manual for detailed intended use, indications, contraindications, warnings, precautions and potential adverse events.

No potential adverse events have been identified with use of the myMerlinPulse™ mobile application.

MAT-1900077 v4.0 | Item approved for Global use.

Abbott